fda update on semaglutide Live Updates on Semaglutide's Current and Future Uses

The FDA's Decision to Ban Compounds: What You Need to Know

28.90

★★★★☆4.8 (126)

On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding

23.06

★★★★★4.9 (98)

FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

28.43

★★★★★5.0 (157)

The FDA has a website for reporting the side effects caused by drugs. It's not a perfect system, but it is a way for us to see trends. Not every event is

29.62

★★★★★4.7 (84)

FDA Warns on Certain Forms of Compounded Semaglutide

28.29

★★★★★4.9 (203)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

27.71

★★★★★5.0 (176)

🚨 FDA Ends Semaglutide Shortage The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant

21.94

★★★★★4.8 (132)